Cargando…

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study

Detalles Bibliográficos
Autores principales:	Ayuk, Francis, Gagelmann, Nico, von Tresckow, Bastian, Wulf, Gerald, Rejeski, Kai, Stelljes, Matthias, Penack, Olaf, Baldus, Claudia D., Kröger, Nicolaus, Bethge, Wolfgang, Dreger, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506090/ https://www.ncbi.nlm.nih.gov/pubmed/37450376 http://dx.doi.org/10.1182/bloodadvances.2023010336

Ejemplares similares

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
por: Gagelmann, Nico, et al.
Publicado: (2022)

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
por: Dreger, Peter, et al.
Publicado: (2022)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
por: Schubert, Maria-Luisa, et al.
Publicado: (2023)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?
por: Gagelmann, Nico, et al.
Publicado: (2021)

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
por: Gagelmann, Nico, et al.
Publicado: (2023)

Reply to Shao and Zhou
por: Gagelmann, Nico, et al.
Publicado: (2022)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2022)

Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2021)

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
por: Fehse, Boris, et al.
Publicado: (2020)

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
por: Niederwieser, Christian, et al.
Publicado: (2022)

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
por: Penack, Olaf, et al.
Publicado: (2023)

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
por: Panagiota, Victoria, et al.
Publicado: (2023)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
por: Badbaran, Anita, et al.
Publicado: (2020)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
por: Korell, Felix, et al.
Publicado: (2022)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients
por: Schubert, Maria-Luisa, et al.
Publicado: (2022)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
por: Berger, Susanna Carolina, et al.
Publicado: (2022)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
por: Penack, Olaf, et al.
Publicado: (2023)

Data-driven grading of acute graft-versus-host disease
por: Bayraktar, Evren, et al.
Publicado: (2023)

Evolution of Matrix Gla and Bone Gla Protein Genes in Jawed Vertebrates
por: Leurs, Nicolas, et al.
Publicado: (2021)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
por: Bader, Peter, et al.
Publicado: (2023)

The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
por: Burns, Ian, et al.
Publicado: (2022)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety
por: Vitanza, Nicholas A., et al.
Publicado: (2023)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
por: Klyuchnikov, Evgeny, et al.
Publicado: (2011)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1hhut17glg88082j68dci5a5jn